Boswellia serrata extract showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
It is very uncertain whether bismuth subsalicylate changes clinical response compared with placebo (very low certainty).
It is very uncertain whether bismuth subsalicylate changes histological response compared with placebo (very low certainty).
Proton pump inhibitors (PPI) probably leads to lower global symptoms of dyspepsia (> 2 weeks) compared with placebo (moderate certainty).
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with placebo (moderate certainty).
It is very uncertain whether anti‐TB therapy changes relapse compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes adverse events compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission or improvement compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in fistula improvement or healing compared with placebo (low certainty).
Azathioprine or 6‐mercaptopurine probably leads to higher steroid sparing effect compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
5‐ASA showed no clear difference in relapse, drop‐outs classed as relapse, grouped by length of compared with placebo (moderate certainty).
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).